Panel Discussion | Are We Ready for Technological Solutions such as Digitally Enabled Cardiac Rehabilitation, and Changing Cath Lab Flow to Change the Practice of Interventional Cardiology?

Monday, March 10, 2025

10:32 AM – 10:50 AM ET

Panel Moderator(s)

Mona Advani, M.Sc., MBA

Principal Regulatory Consultant
CardioMed Device Consultants
HERNDON, Virginia, United States

Disclosure(s): No financial relationships to disclose
Richard E. Galgon, MD, MS

Principal Consultant
CardioMed Device Consultants, LLC
Waunakee, Wisconsin, United States

Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

Rafael Beyar, MD, DSc, MPH

Interventional cardiologists and President
Rambam Hospital/ Rambam Friends Organizations
Haifa, Israel

Disclosure(s): Bio-T: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Cuspa medical: Consultant (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); medhub AI: Stock-privately held company (Ongoing)
Justin E. Davies, MD, PhD

Cardiologist
Imperial College London
London, England, United Kingdom

Disclosure(s): No financial relationships to disclose
Robert Eno, MBA

CEO
HeartBeam Inc
Saratoga, California, United States

Disclosure(s): HeartBeam: Employee (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
David F. Kong, MD, AM, DMT

Associate Professor of Medicine
Duke University
Durham, North Carolina, United States

Disclosure(s): International Business Machines: Grant/Research Support (Ongoing)
Ran Kornowski, MD

Chairman, Department of Cardiology
Rabin Medical Center
Petach-Tikva, Israel

Disclosure(s): Medtronics-Cathworks: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Chaim Shaul Lotan, MD

Chief Innovation Officer
Hadassah-Hebrew University Medical Center
Jerusalem, Israel

Disclosure(s): No financial relationships to disclose
Seth S. Martin, MD, MHS, FACC, FAHA, FASPC

Professor
Johns Hopkins
Reisterstown, Maryland, United States

Disclosure(s): Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Heartflow, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing); New Amsterdam Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)
Siddharth Prakash, MD, PhD

Professor
The University of Texas Health Science Center at Houston

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Mona Advani, M.Sc., MBA: No financial relationships to disclose

Richard E. Galgon, MD, MS: No financial relationships to disclose

Rafael Beyar, MD, DSc, MPH: Bio-T: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Cuspa medical: Consultant (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); medhub AI: Stock-privately held company (Ongoing)

Justin E. Davies, MD, PhD: No financial relationships to disclose

Rob Eno: HeartBeam: Employee (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

David F. Kong, MD, AM, DMT: International Business Machines: Grant/Research Support (Ongoing)

Chaim Shaul Lotan, MD: No financial relationships to disclose

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC: Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Heartflow, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing); New Amsterdam Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)

Sa'ar Minha, MD: Abbott Vascular, Medtronic, Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)